First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.
At present, there are no FDA-approved systemic therapies for patients with high-grade meningiomas. However, there has been an increase in research surrounding the disease over the past decade, which is improving the prospect a targeted agent may become for this population.
Researchers ID potential new drug target in bladder cancer
Experimental drug that reduces protein production slows disease progression in lab studies May 25, 2021 • By Sabrina Richards / Fred Hutch News Service Drs. Andrew Hsieh (left) and Sujata Jana (right) found that blocking protein synthesis slows bladder tumor development and progression in lab studies. Image courtesy of Drs. Andrew Hsieh and Sujata Jana
Reining in protein production could have therapeutic effects on bladder tumors, according to new work published today in the journal JCI Insight.
“This is the first time that it’s been shown that protein synthesis is necessary for efficient bladder cancer development,” said Dr. Andrew Hsieh, a Fred Hutchinson Cancer Research Center bladder and prostate cancer researcher and oncologist.
E-Mail
The Mark Foundation for Cancer Research (MFCR) has awarded seven grants to promising early-career investigators for projects aimed at addressing unmet needs in cancer research. The Emerging Leader Award program empowers scientists to take on innovative, high-risk/high-reward projects that have significant potential to improve outcomes for cancer patients.
The 2021 MFCR Emerging Leaders are pursuing important studies in areas of basic, translational, and clinical cancer research, including probing the function of cancer stem cells in brain cancer, discerning the unique molecular features of lung cancer in older patients, and identifying therapeutic combinations that will increase the effectiveness of immune checkpoint inhibitors across multiple types of cancer.